Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

Abstract Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expre...

Full description

Bibliographic Details
Main Authors: Hai-ping Dai, Wei Cui, Qing-ya Cui, Wen-juan Zhu, Hui-min Meng, Min-qing Zhu, Xia-ming Zhu, Lin Yang, De-pei Wu, Xiao-wen Tang
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Biomarker Research
Subjects:
Chimeric antigen receptor T-cells
CD7
Early T-cell precursor lymphoblastic leukemia/lymphoma
Relapsed / refractory
Online Access:https://doi.org/10.1186/s40364-022-00352-w

Internet

https://doi.org/10.1186/s40364-022-00352-w

Similar Items